SlideShare a Scribd company logo
1 of 13
 As the world continues to battle the
coronavirus pandemic, our scientists and
experts are working determinedly, and with
unprecedented partnership and speed, to bring
forth a vaccine. In collaboration with German
biotech company BioNTech,
we announced that the first participants in the
United States were dosed in the Phase 1/2
study of our COVID-19
mRNA vaccine program. Learn more about the
science and this milestone below:
 Vaccines are designed to prevent disease. A
vaccine stimulates your immune system
to respond and produce antibodies – like it
would be if you were exposed to the virus.
After getting vaccinated, you develop
immunity to that disease, without having to get
the disease first.1
 Vaccines are designed to prevent disease, while
treatments help to manage or cure a disease or
condition.1
 Yes – vaccines undergo extensive testing to
make sure they are safe and effective. Once a
vaccine is licensed, regulatory
authorities routinely monitor its use and
investigate any potential safety concerns.2

 The immunity conveyed by a
vaccine varies. For some vaccines, like polio
vaccines, immunity can last a lifetime,
while for other vaccines, like for
influenza, vaccines are needed annually.3
 Researchers and scientists globally are working to
develop a potential vaccine to prevent COVID-19.
Different groups are using various methods,
or technologies, to design possible COVID-
19 vaccines. Pfizer and BioNTech are focusing on
a technology called mRNA. The program includes four
experimental vaccines in different mRNA
formats. These four candidates were selected
based on pre-clinical studies, which indicated the
vaccine candidates are potentially effective and safe in
protecting against COVID-19.
 Any successful vaccine stimulates the immune system
to produce antibodies against a specific foreign body,
so that after getting vaccinated, a
person develops immunity to a specific infection.1
 mRNA vaccines potentially offer greater
flexibility and quicker development timelines
than traditional vaccines development.

 mRNA – or messenger RNA – is a molecule,
composed of nucleotides linked in a unique order
to convey genetic information for the cells to
produce the proteins or antigens encoded by the
mRNA. Once mRNA in a vaccine is inside of the
body’s cells, the cells use their genetic machinery
to translate the genetic
information and produce the antigens encoded by
the mRNA vaccine. The antigens are then
displayed on the cell surface, where they
are recognized by the immune system which
generates a response, including the production of
antibodies against the antigen.4
 mRNA vaccines have demonstrated a favorable
safety profile in pre-clinical studies.v Unlike
traditional vaccines, they do not use an
inactivated virus, but rather a portion of the
viral sequence encoding for one or more viral
antigens.
 The development of a novel vaccine is a
complex and lengthy process that generally
takes 10 to 15 years.vi Given the current global
scale of the COVID-19 pandemic, we
are working at an unprecedented speed to
develop a potential vaccine in a safe and
responsible way, collaborating closely with
regulatory and health authorities around the
world – compressing stages that have taken
years into months, and those that have taken
months into weeks.
 By the end of 2020, we have the potential to
supply millions of vaccines, subject to success
of the development program and regulatory
approval.
 We will collaborate closely with regulatory and
health authorities around the world to provide
a potential vaccine to areas in greatest
need and assuming success of the development
program and regulatory approval, based on
patient demographic data being produced in
real time and being monitored throughout our
clinical development process.

More Related Content

What's hot

Vaccines updates1
Vaccines updates1Vaccines updates1
Vaccines updates1imaging_70
 
COVID_19 Corona virus
COVID_19 Corona virusCOVID_19 Corona virus
COVID_19 Corona virusnosheensultan
 
COVID vaccination truth & myth
COVID vaccination truth & mythCOVID vaccination truth & myth
COVID vaccination truth & mythgyanikashukla
 
Pfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine AnnouncementPfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine AnnouncementRachelMackelprang
 
Γρηγόρης Ντάκουλας, 4th Health Innovation Conference
Γρηγόρης Ντάκουλας, 4th Health Innovation ConferenceΓρηγόρης Ντάκουλας, 4th Health Innovation Conference
Γρηγόρης Ντάκουλας, 4th Health Innovation ConferenceStarttech Ventures
 
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITSSUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITSGagan Sharma
 
Vaccine development for covid 19
Vaccine development for covid 19Vaccine development for covid 19
Vaccine development for covid 19SaptarshiDas78
 
De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009Annie De Groot
 
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2KuchealArivalagan
 
Covid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platformCovid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platformYashfaJavaid
 
8 crazy covid 19 vaccine myths answered
8 crazy covid 19 vaccine myths answered8 crazy covid 19 vaccine myths answered
8 crazy covid 19 vaccine myths answeredUrgentCareHawaii
 
Covid 19-antibodies-pdf
Covid 19-antibodies-pdfCovid 19-antibodies-pdf
Covid 19-antibodies-pdfELIAS OMEGA
 
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...Guy Boulianne
 
New covid 19 vaccines and trials
New covid 19 vaccines and trialsNew covid 19 vaccines and trials
New covid 19 vaccines and trialsKarthik2205
 
Covid 19 vaccine_rohimah mohamud
Covid 19 vaccine_rohimah mohamudCovid 19 vaccine_rohimah mohamud
Covid 19 vaccine_rohimah mohamudRohimah Mohamud
 

What's hot (20)

Covid 19 vaccines
Covid 19 vaccinesCovid 19 vaccines
Covid 19 vaccines
 
Vaccines updates1
Vaccines updates1Vaccines updates1
Vaccines updates1
 
Types of vaccines
Types of vaccinesTypes of vaccines
Types of vaccines
 
COVID_19 Corona virus
COVID_19 Corona virusCOVID_19 Corona virus
COVID_19 Corona virus
 
COVID vaccination truth & myth
COVID vaccination truth & mythCOVID vaccination truth & myth
COVID vaccination truth & myth
 
Pfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine AnnouncementPfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine Announcement
 
Γρηγόρης Ντάκουλας, 4th Health Innovation Conference
Γρηγόρης Ντάκουλας, 4th Health Innovation ConferenceΓρηγόρης Ντάκουλας, 4th Health Innovation Conference
Γρηγόρης Ντάκουλας, 4th Health Innovation Conference
 
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITSSUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
SUBTOPIC: COVID- 19 vaccine CRITERIA, BENEFITS
 
Vaccine development for covid 19
Vaccine development for covid 19Vaccine development for covid 19
Vaccine development for covid 19
 
COVID-19 Vaccine and Vaccination
COVID-19 Vaccine and VaccinationCOVID-19 Vaccine and Vaccination
COVID-19 Vaccine and Vaccination
 
De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009
 
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
 
Covid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platformCovid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platform
 
8 crazy covid 19 vaccine myths answered
8 crazy covid 19 vaccine myths answered8 crazy covid 19 vaccine myths answered
8 crazy covid 19 vaccine myths answered
 
Covid 19-antibodies-pdf
Covid 19-antibodies-pdfCovid 19-antibodies-pdf
Covid 19-antibodies-pdf
 
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...
COVID-19 Vaccines, The Biological Weapons of Mass Destruction, by Igor Shephe...
 
Covid-19 vaccines
Covid-19 vaccinesCovid-19 vaccines
Covid-19 vaccines
 
Different covid 19 vaccines
Different covid 19 vaccines Different covid 19 vaccines
Different covid 19 vaccines
 
New covid 19 vaccines and trials
New covid 19 vaccines and trialsNew covid 19 vaccines and trials
New covid 19 vaccines and trials
 
Covid 19 vaccine_rohimah mohamud
Covid 19 vaccine_rohimah mohamudCovid 19 vaccine_rohimah mohamud
Covid 19 vaccine_rohimah mohamud
 

Similar to Pfizer GET THE FACTS ON OUR COVID-19 VACCINE CANDIDATES

Prospects and Problems of Development of Candidate Vaccine against COVID 19
Prospects and Problems of Development of Candidate Vaccine against COVID 19Prospects and Problems of Development of Candidate Vaccine against COVID 19
Prospects and Problems of Development of Candidate Vaccine against COVID 19ijtsrd
 
new generation vaccine.pptx
new generation vaccine.pptxnew generation vaccine.pptx
new generation vaccine.pptxIqraIqra72
 
new generation vaccine.pptx
new generation vaccine.pptxnew generation vaccine.pptx
new generation vaccine.pptxIqraIqra72
 
new generation vaccine technology .pptx
new generation vaccine technology  .pptxnew generation vaccine technology  .pptx
new generation vaccine technology .pptxAnh Nguyen
 
Vaccine design
Vaccine design Vaccine design
Vaccine design RESHMA R
 
Coronavirus Pandemic Part III (C): Vaccines (rev01)
Coronavirus Pandemic Part III (C): Vaccines (rev01)Coronavirus Pandemic Part III (C): Vaccines (rev01)
Coronavirus Pandemic Part III (C): Vaccines (rev01)Kumaraguru Veerasamy
 
New عرض تقديمي من Microsoft PowerPoint.pptx
New عرض تقديمي من Microsoft PowerPoint.pptxNew عرض تقديمي من Microsoft PowerPoint.pptx
New عرض تقديمي من Microsoft PowerPoint.pptxdalya shakir
 
Top 5 things you should know about any covid 19 vaccine
Top 5 things you should know about any covid 19 vaccineTop 5 things you should know about any covid 19 vaccine
Top 5 things you should know about any covid 19 vaccineAbdelhamid Naili
 
New generation vaccines production
New generation vaccines productionNew generation vaccines production
New generation vaccines productionD.R. Chandravanshi
 
Vaccines and Type of Vaccines
Vaccines and Type of VaccinesVaccines and Type of Vaccines
Vaccines and Type of VaccinesTathagat Sah
 
Vaccines myths and facts extended
Vaccines myths and facts   extendedVaccines myths and facts   extended
Vaccines myths and facts extendedmarinatesone
 
Vaccines and their clinical phase(1,2,3)
Vaccines and their clinical phase(1,2,3)Vaccines and their clinical phase(1,2,3)
Vaccines and their clinical phase(1,2,3)vivek singh
 
COVID-19 VACCINES
COVID-19 VACCINESCOVID-19 VACCINES
COVID-19 VACCINESimaging_70
 
Vaccines ingles - extendido
Vaccines   ingles - extendidoVaccines   ingles - extendido
Vaccines ingles - extendidomarinatesone
 
Mechanism of different types of vaccines in development
Mechanism of different types of vaccines in developmentMechanism of different types of vaccines in development
Mechanism of different types of vaccines in developmentEmilioMolina23
 
Developing Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic SpeedDeveloping Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic SpeedValentina Corona
 

Similar to Pfizer GET THE FACTS ON OUR COVID-19 VACCINE CANDIDATES (20)

Biotechnology presentation
Biotechnology presentationBiotechnology presentation
Biotechnology presentation
 
Covid 19
Covid 19Covid 19
Covid 19
 
Prospects and Problems of Development of Candidate Vaccine against COVID 19
Prospects and Problems of Development of Candidate Vaccine against COVID 19Prospects and Problems of Development of Candidate Vaccine against COVID 19
Prospects and Problems of Development of Candidate Vaccine against COVID 19
 
new generation vaccine.pptx
new generation vaccine.pptxnew generation vaccine.pptx
new generation vaccine.pptx
 
new generation vaccine.pptx
new generation vaccine.pptxnew generation vaccine.pptx
new generation vaccine.pptx
 
new generation vaccine technology .pptx
new generation vaccine technology  .pptxnew generation vaccine technology  .pptx
new generation vaccine technology .pptx
 
Vaccine design
Vaccine design Vaccine design
Vaccine design
 
Coronavirus Pandemic Part III (C): Vaccines (rev01)
Coronavirus Pandemic Part III (C): Vaccines (rev01)Coronavirus Pandemic Part III (C): Vaccines (rev01)
Coronavirus Pandemic Part III (C): Vaccines (rev01)
 
Vaccines ppt.pptx
Vaccines ppt.pptxVaccines ppt.pptx
Vaccines ppt.pptx
 
Vaccine Development in Global Pandemic (COVID-19)
Vaccine Development in Global Pandemic (COVID-19)Vaccine Development in Global Pandemic (COVID-19)
Vaccine Development in Global Pandemic (COVID-19)
 
New عرض تقديمي من Microsoft PowerPoint.pptx
New عرض تقديمي من Microsoft PowerPoint.pptxNew عرض تقديمي من Microsoft PowerPoint.pptx
New عرض تقديمي من Microsoft PowerPoint.pptx
 
Top 5 things you should know about any covid 19 vaccine
Top 5 things you should know about any covid 19 vaccineTop 5 things you should know about any covid 19 vaccine
Top 5 things you should know about any covid 19 vaccine
 
New generation vaccines production
New generation vaccines productionNew generation vaccines production
New generation vaccines production
 
Vaccines and Type of Vaccines
Vaccines and Type of VaccinesVaccines and Type of Vaccines
Vaccines and Type of Vaccines
 
Vaccines myths and facts extended
Vaccines myths and facts   extendedVaccines myths and facts   extended
Vaccines myths and facts extended
 
Vaccines and their clinical phase(1,2,3)
Vaccines and their clinical phase(1,2,3)Vaccines and their clinical phase(1,2,3)
Vaccines and their clinical phase(1,2,3)
 
COVID-19 VACCINES
COVID-19 VACCINESCOVID-19 VACCINES
COVID-19 VACCINES
 
Vaccines ingles - extendido
Vaccines   ingles - extendidoVaccines   ingles - extendido
Vaccines ingles - extendido
 
Mechanism of different types of vaccines in development
Mechanism of different types of vaccines in developmentMechanism of different types of vaccines in development
Mechanism of different types of vaccines in development
 
Developing Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic SpeedDeveloping Covid-19 Vaccines at Pandemic Speed
Developing Covid-19 Vaccines at Pandemic Speed
 

More from SrinivasaReddy137

covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...SrinivasaReddy137
 
mRNA Research and Innovation Engine
mRNA Research and Innovation EnginemRNA Research and Innovation Engine
mRNA Research and Innovation EngineSrinivasaReddy137
 
oxford university Group B streptococcus
oxford university Group B streptococcusoxford university Group B streptococcus
oxford university Group B streptococcusSrinivasaReddy137
 
What does mRNA do? mRNA produces instructions to make proteins that may treat...
What does mRNA do? mRNA produces instructions to make proteins that may treat...What does mRNA do? mRNA produces instructions to make proteins that may treat...
What does mRNA do? mRNA produces instructions to make proteins that may treat...SrinivasaReddy137
 
OXFORD UNIVERSITY covid-19 phase II/III clinical trail explained
OXFORD UNIVERSITY covid-19 phase II/III clinical trail explainedOXFORD UNIVERSITY covid-19 phase II/III clinical trail explained
OXFORD UNIVERSITY covid-19 phase II/III clinical trail explainedSrinivasaReddy137
 
oxford university covid -19 vaccine
oxford university covid -19 vaccineoxford university covid -19 vaccine
oxford university covid -19 vaccineSrinivasaReddy137
 
New microsoft office power point presentation
New microsoft office power point presentation   New microsoft office power point presentation
New microsoft office power point presentation SrinivasaReddy137
 
New microsoft office power point presentation (4)
New microsoft office power point presentation (4)New microsoft office power point presentation (4)
New microsoft office power point presentation (4)SrinivasaReddy137
 

More from SrinivasaReddy137 (10)

covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
covid-19 Guidance for Industry U.S. Department of Health and Human Services F...
 
change control
change controlchange control
change control
 
mRNA Research and Innovation Engine
mRNA Research and Innovation EnginemRNA Research and Innovation Engine
mRNA Research and Innovation Engine
 
Be Ready for coronavirus
Be Ready for coronavirusBe Ready for coronavirus
Be Ready for coronavirus
 
oxford university Group B streptococcus
oxford university Group B streptococcusoxford university Group B streptococcus
oxford university Group B streptococcus
 
What does mRNA do? mRNA produces instructions to make proteins that may treat...
What does mRNA do? mRNA produces instructions to make proteins that may treat...What does mRNA do? mRNA produces instructions to make proteins that may treat...
What does mRNA do? mRNA produces instructions to make proteins that may treat...
 
OXFORD UNIVERSITY covid-19 phase II/III clinical trail explained
OXFORD UNIVERSITY covid-19 phase II/III clinical trail explainedOXFORD UNIVERSITY covid-19 phase II/III clinical trail explained
OXFORD UNIVERSITY covid-19 phase II/III clinical trail explained
 
oxford university covid -19 vaccine
oxford university covid -19 vaccineoxford university covid -19 vaccine
oxford university covid -19 vaccine
 
New microsoft office power point presentation
New microsoft office power point presentation   New microsoft office power point presentation
New microsoft office power point presentation
 
New microsoft office power point presentation (4)
New microsoft office power point presentation (4)New microsoft office power point presentation (4)
New microsoft office power point presentation (4)
 

Recently uploaded

CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 

Recently uploaded (20)

Epilepsy
EpilepsyEpilepsy
Epilepsy
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 

Pfizer GET THE FACTS ON OUR COVID-19 VACCINE CANDIDATES

  • 1.
  • 2.  As the world continues to battle the coronavirus pandemic, our scientists and experts are working determinedly, and with unprecedented partnership and speed, to bring forth a vaccine. In collaboration with German biotech company BioNTech, we announced that the first participants in the United States were dosed in the Phase 1/2 study of our COVID-19 mRNA vaccine program. Learn more about the science and this milestone below:
  • 3.  Vaccines are designed to prevent disease. A vaccine stimulates your immune system to respond and produce antibodies – like it would be if you were exposed to the virus. After getting vaccinated, you develop immunity to that disease, without having to get the disease first.1
  • 4.  Vaccines are designed to prevent disease, while treatments help to manage or cure a disease or condition.1
  • 5.  Yes – vaccines undergo extensive testing to make sure they are safe and effective. Once a vaccine is licensed, regulatory authorities routinely monitor its use and investigate any potential safety concerns.2 
  • 6.  The immunity conveyed by a vaccine varies. For some vaccines, like polio vaccines, immunity can last a lifetime, while for other vaccines, like for influenza, vaccines are needed annually.3
  • 7.  Researchers and scientists globally are working to develop a potential vaccine to prevent COVID-19. Different groups are using various methods, or technologies, to design possible COVID- 19 vaccines. Pfizer and BioNTech are focusing on a technology called mRNA. The program includes four experimental vaccines in different mRNA formats. These four candidates were selected based on pre-clinical studies, which indicated the vaccine candidates are potentially effective and safe in protecting against COVID-19.  Any successful vaccine stimulates the immune system to produce antibodies against a specific foreign body, so that after getting vaccinated, a person develops immunity to a specific infection.1
  • 8.  mRNA vaccines potentially offer greater flexibility and quicker development timelines than traditional vaccines development. 
  • 9.  mRNA – or messenger RNA – is a molecule, composed of nucleotides linked in a unique order to convey genetic information for the cells to produce the proteins or antigens encoded by the mRNA. Once mRNA in a vaccine is inside of the body’s cells, the cells use their genetic machinery to translate the genetic information and produce the antigens encoded by the mRNA vaccine. The antigens are then displayed on the cell surface, where they are recognized by the immune system which generates a response, including the production of antibodies against the antigen.4
  • 10.  mRNA vaccines have demonstrated a favorable safety profile in pre-clinical studies.v Unlike traditional vaccines, they do not use an inactivated virus, but rather a portion of the viral sequence encoding for one or more viral antigens.
  • 11.  The development of a novel vaccine is a complex and lengthy process that generally takes 10 to 15 years.vi Given the current global scale of the COVID-19 pandemic, we are working at an unprecedented speed to develop a potential vaccine in a safe and responsible way, collaborating closely with regulatory and health authorities around the world – compressing stages that have taken years into months, and those that have taken months into weeks.
  • 12.  By the end of 2020, we have the potential to supply millions of vaccines, subject to success of the development program and regulatory approval.
  • 13.  We will collaborate closely with regulatory and health authorities around the world to provide a potential vaccine to areas in greatest need and assuming success of the development program and regulatory approval, based on patient demographic data being produced in real time and being monitored throughout our clinical development process.

Editor's Notes

  1. AUTHOR: CH.SRINIVASA REDDY M.sc
  2. AUTHOR: CH.SRINIVASA REDDY M.sc
  3. AUTHOR: CH.SRINIVASA REDDY M.sc
  4. AUTHOR: CH.SRINIVASA REDDY M.sc
  5. AUTHOR: CH.SRINIVASA REDDY M.sc
  6. AUTHOR: CH.SRINIVASA REDDY M.sc
  7. AUTHOR: CH.SRINIVASA REDDY M.sc
  8. AUTHOR: CH.SRINIVASA REDDY M.sc
  9. AUTHOR: CH.SRINIVASA REDDY M.sc
  10. AUTHOR: CH.SRINIVASA REDDY M.sc
  11. AUTHOR: CH.SRINIVASA REDDY M.sc
  12. AUTHOR: CH.SRINIVASA REDDY M.sc